Address: Lange Nieuwstraat 1
2800 Mechelen
Belgium
Tel: +32 15 28 74 11
We provide Drug Regulatory Affairs, Medical Writing, Clinical Research services and Scientific Advice to the domestic and international Pharmaceutical Industry, Biotech Companies, Medical Device Manufacturers and Developers of Diagnostic Test Kits.
We know how important it is to provide our services on schedule and on budget. To achieve this goal, our multidisciplinary specialist team:
– has access to a very extensive scientific library and several databases;
– has access to an effective pan-European network within the Pharmaceutical Industry, with Distributors, Contract Manufacturers, Certified Laboratories, CRO’s and Service Providers;
– maintains excellent contacts with the Competent Authorities and University Experts;- collaborates with an Expert Strategy and Evaluation Group whose members have many years of industry experience within the European Regulatory and Clinical Research Area.
Services: Clinical Monitoring Site Management, Clinical Phase III, Information, Late Phase (IV), Legal Representation, Medical Writing, Pharmacovigilance and Drug Safety, Project Management, Regulatory
Historically, Belgium is widely recognized as a major regional hub for clinical development. How would you compare the current environment to 1999, when Archemin was first established, and how has…
PharmaBoardroom was delighted to attend DIA Europe 2024 in Brussels earlier this month, bringing together a veritable who’s-who of the European and global regulatory community. The politicians, regulators, payers, patient…
Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its…
A new piece in the January 2023 edition of DIA’s Global Forum magazine lays out how a new coalition aims to transform the landscape for rare disease treatments in Europe…
UCB has been undergoing a far-reaching digital business transformation, integrating novel approaches across its R&D organisation, including Computer-Aided Drug Design (CADD) and AI, while striving to maintain a patient-centric focus.…
Pfizer’s David Isom and Monica Mihedji, writing in the November 2023 edition of the DIA’s Global Forum magazine, examine how the European Medicines Agency is attempting to integrate the use…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
The European Coalition for Access to Comprehensive Genomic Profiling (ECGP) is a new initiative made up of industry association the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), molecular diagnostics firms Exact…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
Representatives of Belgian associations for innovative pharma, generics and biosimilars, medtech, OTC, biotech, hospitals, and medical professionals share their key agenda priorities. These include where they feel that change is…
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field –…
See our Cookie Privacy Policy Here
